Zynerba Pharmaceuticals, Inc.
(NASDAQ : ZYNE)

( )
ZYNE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
CTLTCatalent, Inc. -0.01%84.102.1%$245.35m
SAVACassava Sciences, Inc. -2.78%10.850.0%$209.31m
HZNPHorizon Therapeutics Plc 0.00%79.675.8%$175.38m
JAZZJazz Pharmaceuticals Plc 0.00%141.492.4%$172.13m
MRNSMarinus Pharmaceuticals, Inc. 0.00%11.267.8%$129.52m
CORTCorcept Therapeutics, Inc. 0.00%17.345.5%$128.22m
VRXValeant Pharmaceuticals International, Inc. 0.07%15.2814.1%$89.91m
MYOKMyoKardia, Inc. 0.00%133.901.8%$63.32m
BHCBausch Health Cos., Inc. 0.07%15.280.0%$62.17m
AMRNAmarin Corp. Plc 0.00%4.001.5%$59.91m
ARGXargenx SE 0.72%257.220.0%$56.32m
SAGESAGE Therapeutics, Inc. 0.00%59.898.6%$45.78m
GWPHGW Pharmaceuticals Plc 0.00%99.506.2%$40.15m
AXSMAxsome Therapeutics, Inc. -0.93%75.751.9%$39.67m
PRGOPerrigo Co. Plc -0.64%45.316.8%$36.96m

Company Profile

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.